

BreastScreen NAS Measure Short Names

The short names are for convenience and are not intended to be self-explanatory. Use the full NAS and/or data dictionary for definitions.

Standard	Level	NAS Measure (short name)	Benchmark/ Monitor
Access/Participation	2	1.1.1(a) Partic 50-74 last 24 months	Monitor
Access/Participation	2	1.1.1(b) Partic 50-69 last 24 months (>=70%)	Benchmark
Access/Participation	2	1.1.2(a) Rescreen R1 50-72 in 27 months	Monitor
Access/Participation	2	1.1.2(b) Rescreen R1 50-67 in 27 months (>=75%)	Benchmark
Access/Participation	2	1.1.3(a) Rescreen R2+ 50-72 in 27 months	Monitor
Access/Participation	2	1.1.3(b) Rescreen R2+ 50-67 in 27 months (>=90%)	Benchmark
Access/Participation	2	1.2.1(a) Partic 50-74 special groups	Monitor
Access/Participation	2	1.2.1(a) (i) Partic 50-74 special groups - indig	Monitor
Access/Participation	2	1.2.1(a) (ii) Partic 50-74 special groups - CALD	Monitor
Access/Participation	2	1.2.1(a) (iii) Partic 50-74 special groups - remote	Monitor
Access/Participation	2	1.2.1(a) (iv) Partic 50-74 special groups - SES	Monitor
Access/Participation	2	1.2.1(b) Partic 50-69 special groups	Monitor
Access/Participation	2	1.2.1(b) (i) Partic 50-69 special groups - indig	Monitor
Access/Participation	2	1.2.1(b) (ii) Partic 50-69 special groups - CALD	Monitor
Access/Participation	2	1.2.1(b) (iii) Partic 50-69 special groups - remote	Monitor
Access/Participation	2	1.2.1(b) (iv) Partic 50-69 special groups - SES	Monitor
Access/Participation	3	1.2.2(a) Percentage of screened women aged 40-49, 75+	Monitor
Access/Participation	3	1.2.2(b) Percentage of recalled women aged 40-49, 75+	Monitor
Cancer Detection	1	2.1.1(a) Cancer invasive R1 50-74	Monitor
Cancer Detection	1	2.1.1(b) Cancer invasive R1 50-69 (>=50/10k)	Benchmark
Cancer Detection	1	2.1.2(a) Cancer invasive R2+ 50-74	Monitor
Cancer Detection	1	2.1.2(b) Cancer invasive R2+ 50-69 (>=35/10k)	Benchmark
Cancer Detection	1	2.1.3(a) Cancer small R1 50-74	Monitor
Cancer Detection	1	2.1.3(b) Cancer small R2+ 50-74	Monitor
Cancer Detection	1	2.1.3(c) Cancer small 50-69 (>=25/10k)	Benchmark
Cancer Detection	2	2.1.4(a) Cancer invasive annual women 50-74	Monitor
Cancer Detection	2	2.1.4(b) Cancer small annual women 50-74	Monitor
Cancer Detection	2	2.1.4(c) Cancer invasive annual women 40-49	Monitor
Cancer Detection	2	2.2.1 (a) DCIS R1 50-74 (mon)	Monitor
Cancer Detection	2	2.2.1 (b) DCIS R1 50-69 (>=12/10k)	Benchmark
Cancer Detection	2	2.2.2 (a) DCIS R2+ 50-74	Monitor
Cancer Detection	2	2.2.2 (b) DCIS R2+ 50-69 (>=7/10k)	Benchmark
Cancer Detection	3	2.2.3 DCIS annual women 50-74	Monitor
Cancer Detection	2	2.3.1(a) Interval cancer 1st year 50-74	Monitor
Cancer Detection	2	2.3.1(b) Interval cancer 1st year 50-69 (<7.5 per 10k)	Benchmark
Cancer Detection	2	2.3.2(a) Interval cancer 2nd year 50-74	Monitor
Cancer Detection	2	2.3.2(b) Interval cancer 2nd year 50-69 (<=15 per 10k)	Benchmark
Cancer Detection	2	2.4.1 Reads by reader (>= 2000)	Benchmark
Cancer Detection	3	2.5.1 Women with up to four images	Monitor
Cancer Detection	3	2.5.2 Tech repeat rate (<=2%)	Benchmark
Cancer Detection	2	2.6.1(a) Annual screening 50-74	Monitor
Cancer Detection	2	2.6.1(b) Annual screening 50-69 (<=10%)	Benchmark
Cancer Detection	3	2.6.2 Annual screening 40-49, 75+	Monitor
Cancer Detection	2	2.6.3 (a) Recall R1 50-74	Monitor
Cancer Detection	2	2.6.3 (b) Recall R1 50-69 (<10%)	Benchmark
Cancer Detection	2	2.6.4 (a) Recall R2+ 50-74	Monitor
Cancer Detection	2	2.6.4 (b) Recall R2+ 50-69 (<5%)	Benchmark
Cancer Detection	2	2.6.5 Recall PPV R1 50-74	Monitor
Cancer Detection	2	2.6.6 Recall PPV R2+ 50-74	Monitor
Cancer Detection	2	2.6.7 Early review (<0.2%)	Benchmark
Assessment	2	3.1.1 Needle biopsies, benign (<5%)	Benchmark
Assessment	2	3.1.2(a) Benign lesions, false positive (0%)	Benchmark

Standard	Level	NAS Measure (short name)	Benchmark/ Monitor
Assessment	2	3.1.2(b) False positive root cause analysis (100%)	Benchmark
Assessment	2	3.1.3 Absolute sensitivity of biopsy (>90%)	Benchmark
Assessment	1	3.1.4 Open biopsies benign R1 (<=0.35%)	Benchmark
Assessment	1	3.1.5 Open biopsies benign R2+ (<=0.16%)	Benchmark
Assessment	3	3.1.6 Specimen imaging (100%)	Benchmark
Assessment	1	3.1.7 Lesions identified first excision (>=95%)	Benchmark
Assessment	1	3.1.8 (a) Diagnosis without excision (>=85%)	Benchmark
Assessment	1	3.1.8 (b) Diagnosis without excision, DCIS vs invasive	Monitor
Timeliness	2	4.1.1 (a) Time to screening 28 days 50-74 (>=90%)	Benchmark
Timeliness	2	4.1.1 (b) Time to screening, days to 90% 50-74	Monitor
Timeliness	2	4.1.2 Time to results 14 days (>=90%)	Benchmark
Timeliness	1	4.2.1 (a) Time to assessment 28 days (>=90%)	Benchmark
Timeliness	1	4.2.1 (b) Time to assessment, days to 90%	Monitor
Timeliness	1	4.2.1 (c) Time to assessment, offered in 28 days	Monitor
Timeliness	2	4.2.2 Results at first assessment visit (>=95%)	Benchmark
Timeliness	2	4.2.3 Assessment visits no more than two (>=95%)	Benchmark
Timeliness	2	4.2.4 Biopsy verbal results 7 days (>=85%)	Benchmark
Timeliness	2	4.2.5 Assessment complete 15 days (>=95%)	Benchmark
Timeliness	2	4.2.6 Assessment results 14 days (100%)	Benchmark
Data Management	2	5.1.1 Histo info received (>=95%)	Benchmark
Data Management	3	5.1.2 Treatment info received (>=95%)	Benchmark

Counts/notes

15 Level 1

50 Level 2

8 Level 3

73 (Combined into 42 Measures)

Naming principles.

Uses general words up front and get more specific as qualifiers at the end.

Parentheses at the end show the benchmark, e.g. "<=90%"

Shaded row indicates a benchmarked standard (unshaded rows are monitoring only)